Who
David A. Ramsay
EVP, President, Drug Delivery
Company insider
Files Form 4 as: EVP, President, Drug Delivery, Halozyme Therapeutics; Director, Savara; Director, La Jolla Pharmaceutical Co.
In numbers
- Trades disclosed
- 248
- Buys
- 76
- Sells
- 4
- Bought
- $4.7M
- Sold
- $423K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 5 Feb 2007
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,232 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,823 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,232 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,823 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $423K5,408 at $78.27 | filing |
| 30 Jun 2026filed 2 Jul 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $423K5,408 at $78.27 | filing |
| 1 Apr 2026filed 2 Apr 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 Dec 2025filed 19 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Sold | $121K20,000 at $6.06 | filing |
| 9 Dec 2025filed 11 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 31 Mar 2025filed 1 Apr 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Bought | $417K150,000 at $2.78 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 18 Nov 2024filed 18 Nov 2024 | SVRA SavaraBiotechnology | SEC FORM 4 Bought | $288K100,000 at $2.88 | filing |
| 14 Dec 2023filed 15 Dec 2023 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 26 May 2023filed 26 May 2023 | SVRA SavaraBiotechnology | SEC FORM 4 Bought | $98K37,124 at $2.63 | filing |
| 25 May 2023filed 26 May 2023 | SVRA SavaraBiotechnology | SEC FORM 4 Bought | $33K12,876 at $2.57 | filing |
News
No headline names them, or the companies they trade most, lately.